GlassScriptPhysician profile
Jacob Vadakekalam
NPI 1316904139
$53,946.12
in general payments reported to CMS, 2019-2025
69 companies · $7,093 in 2025
The $7,093 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,129 · 2020: $12K · 2021: $11K · 2022: $5,129 · 2023: $4,869 · 2024: $4,996 · 2025: $7,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,622.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14,887.90 | 2019-2025 | Jardiance, Lyumjev, Zepbound |
| Valeritas, INC. | $6,006.34 | 2019 | |
| Novo Nordisk INC | $4,789.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Senseonics, Incorporated | $2,800.00 | 2025 | Eversense |
| Astrazeneca Pharmaceuticals LP | $2,430.18 | 2019-2023 | Farxiga |
| Tandem Diabetes Care, INC. | $1,894.41 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $1,775.50 | 2019-2025 | Afrezza |
| Medtronic, INC. | $1,705.85 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,561.18 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Ascensia Diabetes Care US INC. | $1,331.22 | 2023-2025 | |
| Amgen INC. | $1,050.38 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbott Laboratories | $1,009.67 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Radius Health, INC. | $950.50 | 2019-2025 | Tymlos |
| Dexcom, INC. | $936.28 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $798.09 | 2020-2025 | Gvoke Hypopen |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $795.96 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $790.17 | 2019-2025 | |
| Sequel Med Tech, LLC | $725.24 | 2025 | Twiist |
| Antares Pharma, INC. | $718.11 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $705.43 | 2019-2025 | Synthroid, Ubrelvy |
| Beta Bionics, INC. | $696.57 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Recordati_rare_diseases_inc. | $550.65 | 2021-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $542.49 | 2022-2025 | Cequr Simplicity |
| Corcept Therapeutics | $417.51 | 2020-2025 | Korlym |
| Esperion Therapeutics, INC. | $353.46 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $327.66 | 2021-2025 | |
| Amarin Pharma, INC. | $316.17 | 2019-2023 | |
| Medtronic Minimed, INC. | $301.51 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $275.48 | 2019-2022 | |
| Kyowa Kirin, INC. | $210.78 | 2023-2025 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $184.40 | 2020-2022 | |
| Zealand Pharma US, INC. | $161.81 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $140.70 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $121.80 | 2019 | |
| Insulet Corporation | $121.32 | 2019-2025 | Omnipod |
| Lifescan, INC. | $119.61 | 2020-2022 | |
| Companion Medical, INC. | $114.28 | 2019 | |
| Madrigal Pharmaceuticals | $113.53 | 2025 | Rezdiffra |
| Becton, Dickinson and Company | $107.85 | 2020-2022 | |
| Soleno Therapeutics, INC. | $85.51 | 2025 | Vykat Xr |
| Organogenesis INC. | $79.46 | 2022-2023 | Puraply |
| Ipsen Biopharmaceuticals, INC | $79.35 | 2021-2023 | Somatuline Depot |
| Alexion Pharmaceuticals, INC. | $69.62 | 2021-2025 | Strensiq |
| Nalpropion Pharmaceuticals LLC | $63.15 | 2019 | |
| Averitas Pharma INC. | $58.12 | 2023-2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $50.86 | 2020 | |
| Acerus Pharmaceuticals Corporation | $48.80 | 2021-2022 | |
| Almatica Pharma LLC | $46.21 | 2024 | Teriparatide |
| Pfizer INC. | $44.18 | 2024-2025 | |
| Clarus Therapeutics INC. | $42.15 | 2021 | |
| Eusa Pharma (US) LLC | $41.19 | 2022 | |
| Opko Pharmaceuticals, LLC | $36.72 | 2019-2020 | |
| Amphastar Pharmaceuticals, INC. | $32.81 | 2024-2025 | |
| Rhythm Pharmaceuticals, INC. | $32.30 | 2025 | Imcivree |
| Nestle Healthcare Nutrition INC. | $30.92 | 2020-2021 | |
| Tolmar, INC. | $27.46 | 2023 | |
| Roche Diabetes Care, INC. | $24.03 | 2019 | |
| Chiesi USA, INC. | $21.52 | 2024 | Mycapssa |
| Halozyme INC | $21.18 | 2023 | |
| Glaxosmithkline, LLC. | $20.83 | 2025 | Shingrix, Arexvy |
| Grt US Holding, INC. | $20.38 | 2022 | |
| Vivus LLC | $19.49 | 2019-2020 | |
| Amryt Pharma Holdings LTD | $18.54 | 2021 | |
| Ibsa Pharma INC. | $18.50 | 2020 | |
| Horizon Therapeutics Plc | $16.64 | 2020 | |
| Nevro Corp. | $16.49 | 2021 | |
| Currax Pharmaceuticals LLC | $14.51 | 2021 | |
| Intuity Medical INC | $14.22 | 2022 | |
| Optos, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Vadakekalam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.